Abstract 163P
Background
ERCC1 and ERCC2 are major enzymes involved in nucleotide excision repair (NER). Single nucleotide polymorphisms (SNPs) affect the mRNA level and stability resulting in an alteration in protein translation. ERCC1/2 SNPs potentially association with survival in various cancers but the data in CCA was limited.
Methods
We did a retrospective review and genomic DNA analysis from FFPE tissue of patients diagnosed locally advanced or metastatic CCA who received palliative chemotherapy. The target SNPs included ERCC1 C19007T, C8092A and ERCC2 C312T, A2251C.
Results
Genomic DNA analysis was done in 64 patients but only 54 patients received platinum-based chemotherapy were use in the survival analysis. The ERCC1 C19007T CT SNP had a trend to have better OS than wild-type (CC), 8.8 vs 6.3 months respectively, the HR was statistically significant in multivariate survival analysis (HR 0.47 (0.23-0.94), p = 0.032). The ERCC1 C8092A both homozygous (AA) and heterozygous (CA) SNPs had shorter OS compare with wild-type (CC), 6.2, 8.0 and 9.5 months respectively, there was a trend to statistically significant between CT and CC group HR 1.83 (0.96-3.51), p = 0.067. These findings also observe in response rate and disease control rate. Conversely, ERCC2 SNPs did not associate with the outcome.
Conclusions
ERCC1 C19007T and ERCC1 C8092A SNPs are associated with the overall survival but not the ERCC2 SNPs in cholangiocarcinoma patients receiving platinum-based chemotherapy. Longer survival is seen in ERCC1 C19007T heterozygous SNP (CT) but shorter in ERCC1 C8092A.
Clinical trial identification
Human Ethics Committee of Khon Kaen University (HE611254).
Editorial acknowledgement
Legal entity responsible for the study
The author.
Funding
Has not received any funding.
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
504P - A single center report for safety and efficacy of CT-707 in Chinese patients with advanced, anaplastic lymphoma kinase-rearranged non-small cell lung cancer or other tumours
Presenter: Peng Song
Session: Poster display session
Resources:
Abstract
519P - Initial results of lung cancer genomic screening project for individualized medicine in Asia: LC-SCRUM-Asia
Presenter: Chih-Hsi Kuo
Session: Poster display session
Resources:
Abstract
521P - A randomized, phase II study comparing irinotecan versus amrubicin as maintenance therapy after first-line induction therapy for extensive disease small cell lung cancer (HOT1401/NJLCG1401)
Presenter: Keisuke Baba
Session: Poster display session
Resources:
Abstract
526P - A phase II study of apatinib in patients with recurrent/metastatic esophageal squamous cell carcinoma (ESCC)
Presenter: Li Chu
Session: Poster display session
Resources:
Abstract
499P - Prevalence of uncommon epidermal growth factor receptor (EGFR) alterations detected by circulating tumour DNA (ctDNA) in non-small cell lung cancer (NSCLC) patients in Hong Kong
Presenter: Oscar Siu Hong Chan
Session: Poster display session
Resources:
Abstract
489P - Overall survival in patients with EGFRm+ NSCLC receiving sequential afatinib and osimertinib: Updated analysis of the GioTag study
Presenter: Maximilian J. Hochmair
Session: Poster display session
Resources:
Abstract
509P - Second-line treatment after first-line vinorelbine in advanced platinum unfit NSCLC patients: An exploratory analysis of randomized Tempo-Lung trial
Presenter: Andrea Camerini
Session: Poster display session
Resources:
Abstract
500P - Clinico-molecular characteristics of Chinese primary non-small cell lung cancer patients with compound EGFR mutations
Presenter: Jianchun Duan
Session: Poster display session
Resources:
Abstract
527P - A multicenter study of NRG1 fusions in Chinese non-small cell lung cancer patients and response to afatinib using next generation sequencing
Presenter: Xingliang Li
Session: Poster display session
Resources:
Abstract
481P - Updated survival outcomes of the phase II study of low starting dose of afatinib as first-line treatment in patients with EGFR mutation-positive non-small cell lung cancer (KTORG1402)
Presenter: Toshihide Yokoyama
Session: Poster display session
Resources:
Abstract